Figure S14 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
Year: 2026
Type: other
Abstract: Survival outcomes stratified by End of treatment (EOT) optimal PCR response (OPR) (Landmark=6.6 months from therapy initiation, continuous remission)
Authors: Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres E. Quesada, Sanam Loghavi, Koji Sasaki, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Akhil Jain, Mikaela McCabe, Fadi G. Haddad, Mark Brandt, Guilin Tang, Yesid Alvarado, Kayla Farish, Hussein A. Abbas, Guillermo Garcia-Manero, Farhad Ravandi, Michael Andreeff, Gautam Borthakur
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7166817508